Equities

Atlantic International Corp

ATLN:PKC

Atlantic International Corp

Actions
  • Price (USD)5.00
  • Today's Change0.02 / 0.40%
  • Shares traded281.00
  • 1 Year change-39.54%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024 20:44 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Atlantic International Corp., formerly SeqLL Inc., is a strategic staffing, outsourced services, and workforce solutions company. The Company is engaged in servicing the light industrial, commercial, professional, finance, direct placement, and managed service provider verticals, according to Staffing Industry Analysts. It provides its customers with complete HR solutions, operating 40 independent on-site and vendor-on-premises facilities. Its core offerings include staffing and recruitment, program management, data mastery and continuous refinement. Staffing and recruitment offer pioneering client-centric forecasting and staffing solutions. Program management is a bespoke program ensuring longevity and growth in client partnerships. Data mastery is a database solution to monitor usage and pivotal data points. Its subsidiary is Lyneer Investments LLC.

  • Revenue in USD (TTM)205.26m
  • Net income in USD-62.29m
  • Incorporated2014
  • Employees7.00
  • Location
    Atlantic International Corp270 Sylvan Avenue, Suite 2230ENGLEWOOD CLIFFS 07632United StatesUSA
  • Phone+1 (201) 899-4470
  • Fax+1 (302) 636-5454
  • Websitehttp://seqll.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ATLN:PKC since
announced
Transaction
value
Staffing 360 Solutions IncAnnounced04 Nov 202404 Nov 2024Announced-4.40%5.71m
Data delayed at least 15 minutes, as of Nov 12 2024 20:44 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Nevro Corp419.15m-69.31m198.35m1.22k--0.7279--0.4732-1.89-1.8911.407.310.72441.106.01344,976.10-11.98-13.64-14.11-16.6868.0268.54-16.54-20.673.76-9.480.4482--4.631.88-3,172.74--0.9012--
Accuray Inc444.20m-20.08m199.12m987.00--4.40--0.4483-0.2032-0.20324.480.45030.93532.015.25450,054.70-4.23-1.37-7.35-2.3331.0936.43-4.52-1.550.8655-0.09360.7901---0.23551.29-67.51---3.54--
Neuropace Inc71.82m-29.90m212.55m171.00--21.46--2.96-1.09-1.092.610.33920.73051.746.49419,994.20-30.41---34.66--74.15---41.63--5.47-4.370.8565--43.72--30.00------
Trubridge Inc336.56m-52.28m213.61m3.22k--1.18--0.6347-3.68-3.6823.6412.120.7947196.765.88104,553.30-12.661.25-14.341.4148.7050.40-15.931.561.760.61150.498545.063.913.89-387.73--88.71--
Electromed Inc54.72m5.15m225.59m174.0046.355.2037.654.120.57910.57916.175.161.123.272.25314,459.8010.518.6412.5110.0976.2676.269.418.065.27--0.000.0013.8311.8262.6721.06-22.23--
Sight Sciences Inc79.40m-52.32m230.91m214.00--2.26--2.91-1.06-1.061.612.030.4741.534.18371,004.70-31.24-38.78-34.01-42.2085.8080.74-65.90-105.1410.50-26.500.2494--13.6360.8435.59--6.77--
Orchestra Biomed Holdings Inc2.08m-55.58m231.86m56.00--4.98--111.53-1.57-1.570.05861.230.0211.3416.5737,125.00-56.06---64.66--92.02---2,673.26--4.58--0.00---21.88---37.91------
Utah Medical Products, Inc.46.58m15.63m238.25m169.0015.821.9312.055.124.334.3312.9235.450.35761.9912.81275,609.5012.0012.6912.4313.1958.9961.5733.5630.5123.68--0.0037.05-3.933.640.98341.659.711.86
Atlantic International Corp205.26m-62.29m249.73m7.00--9.54--1.22-8.72-8.7214.590.52222.91--7.0329,322,780.00-88.44-71.97-174.30-106.0910.7061.01-30.35-1,471.82---1.330.7735---100.00---37.43------
Anika Therapeutics Inc164.17m-97.52m250.00m357.00--1.39--1.52-6.64-6.6411.1412.240.58681.475.21459,854.30-34.86-5.41-38.55-5.8762.7060.70-59.40-12.603.78--0.00--6.679.56-456.34--3.11--
Jin Medical International Ltd20.13m2.91m252.04m245.0086.379.6082.7012.520.01860.01860.12920.16760.55762.384.2282,143.597.8012.8111.2720.9234.7333.5813.9914.602.27--0.27020.003.29-1.076.34-4.80-9.50--
Inogen Inc326.65m-92.44m261.38m834.00--1.39--0.8002-3.97-3.9713.977.910.95626.857.49391,670.30-27.06-8.23-33.51-9.5342.5644.54-28.30-10.312.37--0.00---16.32-2.49-22.30--26.34--
Zynex Inc193.67m4.82m296.16m1.10k62.808.4131.671.530.14810.14815.911.111.402.577.05176,059.103.4814.584.0617.5280.2079.622.4910.443.154.150.6246--16.5442.01-42.910.37412.19--
Pulmonx Corp79.30m-57.11m298.13m279.00--3.17--3.76-1.47-1.472.042.380.451.247.29284,236.60-32.41-26.27-36.42-28.9774.1671.95-72.01-93.766.77--0.2839--27.9827.98-3.26--20.62--
AngioDynamics, Inc.292.73m-243.03m302.32m748.00--1.55--1.03-6.04-6.047.254.790.74342.276.55391,344.90-61.72-16.38-74.39-18.7051.7152.95-83.02-30.491.41--0.00---10.282.35-251.53--13.09--
LifeMD Inc178.28m-26.60m305.79m207.00------1.72-0.7004-0.70044.70-0.1013.596.8638.19861,255.40-44.31-153.05-333.96-526.9188.9283.66-12.34-45.440.8327-8.191.13--28.1578.9051.27--143.64--
Data as of Nov 12 2024. Currency figures normalised to Atlantic International Corp's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.